The global adult pediatric hemoconcentrators market size was valued at USD 10.57 billion in 2025 and is projected to grow from USD 11.20 billion in 2026 to USD 17.75 billion by 2034, registering a CAGR of 5.93% during the forecast period (2026-2034). North America dominated the adult pediatric hemoconcentrators market with a share of 39.11% in 2025.
Adult pediatric hemoconcentrators remove excess water and low molecular weight substances from blood while retaining blood cells and larger proteins. Hemoconcentrators are commonly classified under HSN Code 9018 (instruments and appliances used in medical or surgical sciences) and SIC Code 3841 (Surgical and Medical Instruments and Apparatus).
The adult pediatric hemoconcentrators market demand is driven by the need for effective fluid management and controlled blood concentration during cardiac procedures. Cardiac surgery teams are using adult hemoconcentrators and pediatric hemoconcentrators to remove excess fluid, manage hematocrit levels, and support appropriate blood volume control across different patient groups.
Download a Free Sample To learn more about this report,
Integration of Hemoconcentrators with Cardiopulmonary Bypass Systems
The adult and pediatric hemoconcentrators market analysis shows the integration of hemoconcentrators with cardiopulmonary bypass systems used during cardiac surgery. These devices remove excess water and selected small solutes from blood while retaining blood cells and larger proteins, helping manage fluid balance and increase hematocrit levels during or after bypass procedures.
Adoption of Hemoconcentration in Neonatal Cardiac Procedures
Hemoconcentration in neonatal cardiac procedures is shaping the adult and pediatric hemoconcentrators market, particularly for infants undergoing surgery for congenital heart defects. Neonates have small circulating blood volumes, making careful management of fluid balance and blood dilution especially important during cardiopulmonary bypass.
Supply chain disruptions are expected to have a high impact on the adult pediatric hemoconcentrators market share due to dependence on medical-grade membranes, polymer components, and sterile medical device materials. The market is expected to follow a stair-step recovery, as shortages of specialized materials and transportation disruptions can affect device production. The market is expected to grow at a CAGR of 5.93%, but supply chain constraints could lower this by 0.8 percentage points, resulting in a growth of around 5.13%. As supply conditions normalize, the adult pediatric hemoconcentrators market growth is expected to gradually return to 5.93%.
The adult and pediatric hemoconcentrators market forecasts strategic investment activity driven by improvements in extracorporeal blood processing and advances in fluid management during cardiac surgery. In May 2026, Orchestra BioMed received a USD 20 million payment from Medtronic under a previously announced financing agreement. The funding supports completion of a pivotal clinical trial for its blood pressure therapy, not hemoconcentrators directly.
Demand for Effective Fluid Management and Hematocrit Control During Extracorporeal Circulation Drives Market
Demand for effective fluid management during cardiac surgery is supporting the adult and pediatric hemoconcentrators market, as cardiopulmonary bypass procedures can increase excess fluid in the blood. Hemoconcentrators help remove excess water and selected small solutes from circulating blood, allowing clinicians to manage fluid balance during surgery.
Need for hematocrit control during extracorporeal circulation is contributing to market growth as cardiopulmonary bypass can dilute blood and reduce hematocrit levels. Hemoconcentrators remove excess plasma water, helping increase hematocrit and concentrate blood components when clinically appropriate.
Risk of Blood Cell Damage and Stringent Regulatory Approval Requirements Restrain Market Expansion
Hemoconcentration can cause cell damage if blood filtration pressure, flow rates, or operating conditions are not properly controlled. Excessive mechanical stress may affect red blood cell integrity and contribute to hemolysis, potentially compromising patient safety during cardiac surgery. Adult and pediatric hemoconcentrators must meet strict regulatory requirements for safety, performance, biocompatibility, and manufacturing quality. These requirements may increase development costs and extend approval timelines, delaying product launches and creating challenges for manufacturers entering the market.
Expansion of Hemoconcentrator Use in Complex Cardiac Surgeries and Organ Transplant Procedures Offers Growth Opportunities
Medical device manufacturers can target cardiac surgery centers, hospitals, and perfusion system departments that require effective fluid management during cardiopulmonary bypass procedures. Hemoconcentrators help remove excess plasma water and reduce fluid overload while retaining important blood components during extracorporeal circulation. Revenue opportunities arise through device sales, disposable hemoconcentrator supplies, hospital procurement contracts, and partnerships with cardiac surgery equipment providers.
Medical device manufacturers can target hospitals and transplant centers performing procedures that require extracorporeal circulation and careful fluid management. Hemoconcentrators can help remove excess fluid and concentrate blood during selected surgical procedures, depending on clinical protocols. Market players can bank on device sales, disposable supplies, equipment integration, and long-term procurement agreements with specialized surgical centers, supporting adult and pediatric hemoconcentrators market growth.
Portable hemoconcentrators will expand to 6.52% CAGR during the forecast period, driven by demand for flexible and convenient fluid management during extracorporeal procedures.
Stationary hemoconcentrators are projected to grow at a CAGR of 5.47% during the forecast period, supported by their use in established perfusion setups and cardiac surgery procedures. These systems help remove excess fluid from blood while retaining blood components during extracorporeal circulation.
Request Customizationto receive a tailored report.
Ultrafiltration dominated the filtration method segment with a 51.46% share, owing to its widespread use for removing excess plasma water and small solutes while retaining blood cells and larger proteins.
Membrane filtration segment is anticipated to grow at a CAGR of 5.82% during the forecast period, driven by the need for controlled fluid removal during extracorporeal blood processing. Membrane based systems support selective separation according to membrane properties and operating conditions.
Cardiopulmonary bypass accounted for the largest share at 38.71%, reflecting the use of hemoconcentrators to remove excess fluid and concentrate blood during cardiac surgery. This helps manage fluid balance and supports blood conservation during extracorporeal circulation.
Extracorporeal support will expand to 6.63% CAGR during the forecast period, propelled by the need for fluid management during prolonged extracorporeal therapies.
Hospitals held the leading position with a 49.62% share, supported by the availability of cardiac surgery departments, perfusion teams, and specialized extracorporeal treatment facilities. Hospitals use hemoconcentrators during cardiac procedures and other treatments requiring controlled fluid removal from blood.
Ambulatory surgical centers segment will achieve a growth rate of 6.56% during the forecast period, supported by the expansion of outpatient surgical services and demand for efficient perioperative critical care.
Speak to an Analystto discuss market opportunities.
North America's adult pediatric hemoconcentrators market accounted for a dominant share of 39.11% in 2025.
The American Society of ExtraCorporeal Technology (AmSECT) updated its pediatric and congenital perfusion standards to strengthen blood management during cardiopulmonary bypass, including the use of ultrafiltration to reduce hemodilution and support appropriate blood cell concentrations. These recommendations reinforce the role of pediatric hemoconcentrators in managing fluid balance and preserving blood components during congenital heart surgery.
Canadian pediatric cardiac surgery services use ultrafiltration during cardiopulmonary bypass to remove excess fluid and concentrate blood components in infants and children undergoing congenital heart procedures. These techniques help manage hemodilution associated with bypass circuit priming and support blood conservation in patients with limited circulating blood volume.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific adult pediatric hemoconcentrators market is projected to grow at a CAGR of 7.13% during the forecast period, making it the fastest-growing region.
At the All India Institute of Medical Sciences (AIIMS), New Delhi, a clinical study evaluated conventional and modified ultrafiltration in children undergoing cardiac surgery with cardiopulmonary bypass. The combined approach improved hematocrit levels and reduced postoperative chest drainage, demonstrating the clinical role of hemoconcentration in pediatric cardiac procedures.
Japanese National Cerebral and Cardiovascular Center in Osaka provides specialized treatment for congenital and complex cardiovascular conditions, including pediatric heart surgery requiring cardiopulmonary bypass. These procedures involve careful control of circulating blood volume, creating a clinical role for hemoconcentrators to remove excess fluid and concentrate blood during extracorporeal circulation.
China’s Fuwai Hospital in Beijing performs complex cardiovascular surgeries, including procedures for congenital heart defects that require cardiopulmonary bypass. Hemoconcentrators can be used during extracorporeal circulation to remove excess plasma water and concentrate blood components, helping surgical teams manage hemodilution and fluid balance during cardiac procedures.
Europe's adult pediatric hemoconcentrators market is expected to experience a growth rate of 5.67% during the forecast period.
The UK’s National Institute for Health and Care Excellence (NICE) describes Hemosep, a blood ultrafiltration and hemoconcentration system available in adult and pediatric sizes, for concentrating residual blood from cardiopulmonary bypass circuits. The technology supports fluid management by removing excess plasma water while retaining blood cells, helping preserve concentrated blood for return to patients after cardiac surgery.
Germany’s cardiac perfusion practice follows European cardiopulmonary bypass guidance that recognises ultrafiltration for fluid management and blood concentration during cardiac surgery. The guidance covers conventional and modified ultrafiltration to remove excess fluid and electrolytes while retaining blood cells and proteins, highlighting the role of hemoconcentrators in extracorporeal circulation and perioperative blood management.
The Latin America adult pediatric hemoconcentrators market is expected to achieve a growth rate of 5.36% during the forecast period. Brazil’s perfusion practice standards, developed by the Brazilian Society for Cardiovascular Surgery and the Brazilian Society for Extracorporeal Circulation, address equipment management, hematocrit control, and safety protocols during cardiopulmonary bypass.
Mexico’s Instituto Nacional de Cardiología Ignacio Chávez provides specialised cardiovascular surgery services, including treatment for complex congenital heart conditions. Its cardiac surgery procedures involving cardiopulmonary bypass require effective fluid management and blood conservation.
The Middle East & Africa adult pediatric hemoconcentrators market is estimated to register a growth rate of 5.11% during the forecast period. UAE’s specialized perfusion services include conventional and modified ultrafiltration during adult and pediatric cardiac surgery. These procedures remove excess fluid and concentrate blood components during cardiopulmonary bypass.
South Africa’s Chris Barnard Division of Cardiothoracic Surgery at Groote Schuur Hospital and Red Cross War Memorial Children’s Hospital provides adult and pediatric cardiopulmonary bypass services, including cell salvage and related perfusion procedures.
The adult pediatric hemoconcentrators market competitive landscape is highly fragmented, with established medical device manufacturers, extracorporeal blood processing specialists, and perfusion technology companies. Key players such as Terumo Corporation, Medtronic, LivaNova, Weigao Medical International Co., and Medica S.p.A. are estimated to account for 30–35% of the global adult pediatric hemoconcentrators market share.
Established players compete mainly through filtration efficiency, blood component retention, and device biocompatibility. Emerging and regional players in the adult pediatric hemoconcentrators market ecosystem focus on specialized filtration technologies and application-specific solutions for adult, pediatric, and neonatal cardiac procedures.
April 2026: Terumo Corporation continued to offer its CAPIOX adult and pediatric hemoconcentrator range for cardiac surgery and cardiopulmonary bypass procedures.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Handheld Backscatter X-Ray Devices Market Size, Share, Growth, 2034
Arterial Cannula Market Size, Forecast, Demand, Opportunities, 2034
Ultrasound Devices Market Size, Share, Growth, Analysis, 2034
Catheter Directed Thrombolysis Market Size, Forecast, Demand, Opportunities, 2034
Breast Biopsy Device Market Size, Forecast, Opportunities, 2034
Antimicrobial Hospital Textile Market Size, Forecast, Opportunities, 2034
We are featured on:
sales@straitsresearch.com